Policy & Regulation: Page 18

PharmaVoice Team/PharmaVoice

Who's on the List by Company

Anavex Life Sciences Cameron Durrant, M.D. 18 ApotheCom David Dunn 16 Astellas Pharma US Margaret Long 73 AstraZeneca David Brennan 46 bioCapture Johanna Allston, Ph.D. 12 C3i Robert Piwko 112 Cegedim Dendrite Angela Miccoli 74 Cipla Ltd. Yusuf Hamied, Ph.D. 19 ClearTrial Mike Soenen 29 closerloo...
By PharmaVoice Team • July 28, 2010
PharmaVoice Team/PharmaVoice

Letter from the Editor

The PharmaVOICE 100: 2010 Every year, I think this is it, we’ve reached the pinnacle. And yet, every year, I continue to be amazed by the individuals whom our readers have identified as the most inspiring, motivating, and outstanding leaders in the life-sciences industry. This special issue, n...
By Taren Grom • July 28, 2010
Explore the Trendline➔

Stock via Getty Images

Trendline

Emerging biotech

After years of financial turmoil, the biotech market is turning the page. Strong fundamentals, including solid clinical data, are key for biotechs hoping to capitalize on the improving conditions.
By PharmaVoice staff
PharmaVoice Team/PharmaVoice

ACRP 2010 Global Conference & Exhibition Wrap Up

The Association of Clinical Research Professionals (ACRP) remains steadfast in its mission to provide value and excellence to conference participants against a backdrop of continued economic and regulatory challenges to individuals and businesses. This year’s conference featured 55 sessions and 2...
By PharmaVoice Team • May 27, 2010
PharmaVoice Team/PharmaVoice

PharmaOutlet

Reputation malaise has made the U.S.-based pharmaceutical industry vulnerable to “Beltway advocacy." Science has lost its life-enhancing societal mystique and at risk is its intellectual property. Drug-discovery successes and the stellar reputation of the 1980s and 1990s — driving breakthrough tr...
By Gil Bashe • May 24, 2010
PharmaVoice Team/PharmaVoice

Last Word

The Impact What will be the impact of the federal legislation requiring companies to disclose financial transactions with providers? Fisher. The federal legislation is not going to hugely impact pharmaceutical companies. The PhRMA guidelines cover a lot of this already. The biggest change is how ...
By PharmaVoice Team • April 29, 2010
PharmaVoice Team/PharmaVoice

Letter from the Editor

Forms, forms, and more forms… We’ve probably all been hospitalized at one time in our lives, and during whatever span of time we had to spend there, we probably experienced one or two moments of concern when we were repeatedly asked the same questions by a variety of well-meaning practitioners. S...
By Taren Grom • April 28, 2010
PharmaVoice Team/PharmaVoice

Software as a Service: Gaining Traction

Many research firms have predicted that the worldwide economic recession is responsible for the global increase in the software-as-a-service (SaaS) market revenue. According to a recent Gartner report, SaaS is forecast to have a 17.7% compound annual growth rate through 2013 for the aggregate ent...
By PharmaVoice Team • March 23, 2010
PharmaVoice Team/PharmaVoice

Talent Pool

Pharmaceutical POOL Dr. Jay FEINGOLD DSI Strengthens Expertise in Oncology Daiichi Sankyo Inc. (DSI) has appointed Jay Feingold, M.D., Ph.D., to manage the strategic direction of its medical affairs department as VP of medical affairs. DSI is the U.S. subsidiary of Tokyo-based Daiichi Sankyo Co.,...
By PharmaVoice Team • March 22, 2010
PharmaVoice Team/PharmaVoice

Launch: Safety Counts

Approval is no longer the final step," says Anne Tomalin, president of i3 CanReg. “Companies need to consider the possibility that their product may have to be removed from the market one to two years down the road because a safety signal develops." In addition to collecting data and managing a d...
By Robin Robinson • March 4, 2010
PharmaVoice Team/PharmaVoice

The New Washington Office

The legislative push for healthcare reform came with a speed and scope that surprised many in the pharmaceutical industry, drawing new attention to the Washington, D.C., offices of many drug companies. With this new attention comes the potential for new roles and responsibilities for Washington-b...
By Dennis R. Cryer • Jan. 26, 2010
PharmaVoice Team/PharmaVoice

Reducing Regulatory Risk for the Development of Drugs, Biologics, and Devices

Thorough review of all FDA activity in the area of clinical development provides insights into regulatory risks. This information can be used to: n Evaluate and review clinical investigators and CROs. n Develop effective strategies for managing clinical initiatives. n Establish improved monitorin...
By Michael Kuehne • Jan. 26, 2010
PharmaVoice Team/PharmaVoice

A 360-Degree View of E-Patient Connections

Healthcare information technology has created the platform for the exchange, collection, and documentation of health data and information, but it is up to the crucial players — patients, physicians, pharma companies, and service providers — to make e-connections work. The patient, the physician, ...
By PharmaVoice Team • Jan. 26, 2010
PharmaVoice Team/PharmaVoice

Talent Pool

Biotechnology POOL Dr. Paul LAMMERS Mirna Appoints Chief Executive Mirna Therapeutics has named Paul Lammers, M.D., president and CEO. As head of Mirna, Dr. Lammers is responsible for driving the company’s discoveries in the field of microRNA (miRNA) into the clinic. Dr. Lammers was previously pr...
By PharmaVoice Team • Jan. 26, 2010
PharmaVoice Team/PharmaVoice

E-Media

E-MEDIA NEW ELECTRONIC AND WEBBASED APPLICATIONS, SITES, AND TECHNOLOGIES FDAnews has launched Drug Industry Daily, an electronic daily publication that provides news coverage of what’s happening on Capitol Hill, in the courts, and at the Food and Drug Administration, the Federal Trade Commission...
By PharmaVoice Team • Jan. 14, 2010
PharmaVoice Team/PharmaVoice

What's New

NEW HEALTHCARERELATED PRODUCTS, SERVICES, AND COMPANIES Doctors+Designers has changed its company name to HealthEd to reflect a change in business strategy focusing on developing patient-centered health education programs. “With noncompliance costing the pharmaceuti cal industry $15 billion to $2...
By PharmaVoice Team • Jan. 14, 2010
PharmaVoice Team/PharmaVoice

The IRS vs. Independent Contractors

Many pharmaceutical companies are now using independent contractors in increasing numbers; in many cases, these contractors are former employees. What started off as a trickle a few years ago has become a torrent. Quite often, former employees — whether they left voluntarily or not — end up back ...
By Andrew E. Schultz • Jan. 11, 2010
PharmaVoice Team/PharmaVoice

Contents

In Every Issue 3 Letter from the Editor 8 Upfront A brief review of industry news at press time 36 Pharma Trax Sales, marketing, and R&D trends from industry analysts 40 What’s New New healthcare-related products, services, and companies 42 E-Media New electronic and Web-based applications, s...
By PharmaVoice Team • Dec. 28, 2009
PharmaVoice Team/PharmaVoice

Name That Brand: A Pilot Program

The eventual outcome of the FDA’s two-year Proprietary Name Review pilot project may have positive implications for the industry in the long run, but in the short term, it means more money spent and more time pressure for marketers. Our experts say the burden on pharma companies to conduct their ...
By Robin Robinson • Dec. 28, 2009
PharmaVoice Team/PharmaVoice

The Salesforce of the Future

Our experts agree: the salesforce of the future will be more specialized, more technically advanced, and more clinically savvy; oh, and there will be fewer feet on the street, finally. If the past year is any indication, the salesforce of the future is going to experience an extreme makeover. For...
By PharmaVoice Team • Nov. 10, 2009
PharmaVoice Team/PharmaVoice

The Innovation Challenge

There has been a great deal of discussion related to the challenges hampering innovation to create differentiated medicines. Never before have research and cutting-edge science been more important to ensure a steady flow of innovation. Much has been made of the industry’s decline in R&D pro...
By PharmaVoice Team • Nov. 10, 2009
PharmaVoice Team/PharmaVoice

Supply Chain Strategies

Companies need to evaluate their business through their value streams rather than by individual processes or components. ccording to Bob Silvers, managing director, at SSA & Co., by applying the rigors of Lean Six Sigma to underperforming areas, pharmaceutical companies can completely transfo...
By Denise Myshko • Nov. 10, 2009
PharmaVoice Team/PharmaVoice

Talent Pool

Pharmaceutical POOL Stanley BARSHAY Dr. Richard BOWLES Richard CLARK Willie DEESE Kenneth FRAZIER Dr. Peter KIM Raul KOHAN Merck Unveils Post-Merger Organizational Structure Merck has announced its new organizational structure following the completion of its merger with Schering-Plough. The new M...
By PharmaVoice Team • Nov. 10, 2009
PharmaVoice Team/PharmaVoice

On the Calendar

November 16-17 Pharmaceutical Coverage & Reimbursement Conference Washington, D.C. Q1 Productions, q1productions.com November 16-17 The 3rd Pediatric Clinical Trials Grand Hyatt Washington, Washington, D.C. ExL Pharma, exlpharma.com November 17-18, 2009 13th Advanced Forum on Structuring, Neg...
By PharmaVoice Team • Nov. 9, 2009
PharmaVoice Team/PharmaVoice

CRM: Connecting the Dots...

CUSTOMER RELATIONSHIP MANAGEMENT BY TAREN GROM CRM requires a multilevel, enterprisewide view of customers — thereby demanding a strong customer data management business practice . A 5% increase in customer retention can lead to a 25% to 85% profit increase,depending on the industry. — HarvardBus...
By PharmaVoice Team • Nov. 4, 2009
PharmaVoice Team/PharmaVoice

Talent Pool

Pharmaceutical POOL Dr. Per FALK Novo Nordisk Names Clinical Research Head for North America Novo Nordisk, a global healthcare company focusing on diabetes care, has appointed Per Falk, M.D., Ph.D., as VP for clinical, medical, and regulatory affairs for North America. Dr. Falk leads clinical res...
By PharmaVoice Team • Sept. 28, 2009